Navigation Links
Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
Date:2/16/2010

BEDFORD, Ohio, Feb. 16 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line.  This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.  Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)

Bedford Laboratories will supply Indomethacin for Injection USP as single dose vials containing indomethacin sodium, equivalent to 1 mg indomethacin.  "We are very excited and pleased to announce the launch of this critical product.  The release of this product to the market place is very timely, given that the innovator product is currently on long-term backorder (source: www.fda.gov). This is a great milestone for Bedford Laboratories and we are very proud to add this product to our growing portfolio," said David Gaugh, Vice President and General Manager, Bedford Laboratories.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.

Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue employs more than 1,300 people.  For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies (Ingelheim, Germany). For more information, please visit http://us.boehringer-ingelheim.com.

Indocin® is a registered trademark of Lundbeck, Inc.

SOURCE Bedford Laboratories

RELATED LINKS
http://www.bedfordlabs.com

'/>"/>

SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Solentim, the developer of instrumentation for ... a major new product line called the VIPS™ ... has been developed for automatically seeding single cells ... of the process to generate clonally-derived cell lines. ... reliable solution when compared to traditional single cell ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... the continuation of its strategic partnership with and platinum sponsorship of Global Spine ... the safe and effective management of complex spine deformity cases, particularly in children. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
(Date:4/24/2017)... DC (PRWEB) , ... April 24, 2017 , ... The ... recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on ... Santana Telehealth Project for using telemedicine to improve the lives of the poor and ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
Breaking Medicine News(10 mins):